Phase 2 N=6 Rilonacept for Deficiency of the Interleukin-1 Receptor Antagonist (DIRA)
DIRA
Primary: Number of Subjects Who Maintained Inflammatory Remission With Rilonacept — 6 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=1,066 eValuating iDA Selection Ability. The VISA Study.
IVF · Infertility
Primary: Clinical Pregnancy Rate — 257; 248 Participants
Phase 2 N=154 Safety and Efficacy of IDA for Onchocerciasis
Onchocerciasis
Primary: Rates of Severe Adverse Events (SAEs) Across Study Arms — 0; 0; 0 Participants
N/A N=1,013 Inappropriate Shock Reduction wIth PARAD+ Rhythm DiScrimination
Tachycardia
Primary: Patients With Inappropriate Shock(s) — 1.4 Percentage of pts with inap shocks
N/A N=11,157 Tolterodine Drug Use Investigation.(Post Marketing Commitment Plan)
Overactive Bladder
Primary: Confirmation of the Incidence of All Treatment Related Adverse Events (TRAEs). — 984 participants
Phase 1 N=11 Doravirine, Rifapentine and Isoniazid Interaction
Latent Tuberculosis · Human Immunodeficiency Virus · Rifamycins Causing Adverse Effects in Therapeutic Use
Primary: Doravirine Maximum Concentration (Cmax) — 1.7; 1.3 ug/mL
N/A N=354 DATAS: The Dual Chamber & Atrial Tachyarrhythmias Adverse Events Study
Ventricular Tachycardia · Ventricular Fibrillation · Defibrillators, Implantable
Primary: CSAE-score Rate(Clinical Significant Adverse Events Score Rate) — 0.112; 0.128; 0.075 score/month — p=0.0028
N/A N=89 The DECIDE Parent-Provider Intervention
Modified DECIDE Intervention · Treatment as Usual Care Group
Primary: Change in Parent Needs & Resources Domain of CANS - Provider Arm Only — 0 units on a scale — p=0.125
Phase 4 N=237 Shiga Microalbuminuria Reduction Trial-2
Type 2 Diabetes Mellitus · Hypertension
Primary: Reduction in Albuminuria — -5.5; -6.7 percentage of UACR change